A Multicenter, Open-Label, 24-Week, Uncontrolled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil Extended Release Tablets Following Transition From Remodulin or Inhaled Prostacyclin Therapy or as Add-on to Current PAH Therapy in De Novo Prostacyclin Pediatric Subjects Aged 7 to 17 Years With Pulmonary Arterial Hypertension
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 09 Aug 2017 Status changed from active, no longer recruiting to completed.
- 17 Feb 2017 Status changed from recruiting to active, no longer recruiting.